This seems to be a golden-egg laying goose owing particularly to the fact that it generates little pollution, but high returns over an extended period of time. However, because the R & D and clinical trial stages are time-consuming, costly, and carry a high risk of failure, Taiwan's pharmaceuticals industry--dominated as it is by medium-sized or even small firms--has made little headway in this field.
特別是新藥研發製造，因低污染、高效益、回收期長，向來被視為不能錯過的金雞母，但也因整個研發及臨床試驗過程耗時久、風險高、所費不貲等因素，導致以中小企業為主幹的台灣醫藥界，在這方面遲遲未能有所進展。